Azilsartan can restore circadian rhythm of the urinary sodium excretio

Not Applicable

• Conditions: Chronic Kidney Disease (CKD)

• Registration Number: JPRN-UMIN000009549
• Lead Sponsor: Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences

Brief Summary

Twenty patients has been enrolled to the study. Published on Physiological Report

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-14
• Study Completion: 2015-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1. previous treatment with ARB, or diuretics 2 months before enrollment 2. change in the antihypertensive medication 2 months before enrollment 3. contraindication to Azilsartan (history of allergic reaction to it, bilateral renal artery stenosis) 4. presence or possibility of pregnancy/lactation 5. HbA1c >9.0 % 6. GOT >100, or GPT >85 7. endocrine hypertension 8. accelerated o r malignant hypertension (progressive renal dysfunction with diastolic BP of >120-130 mmHg 9. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 10. nephrotic syndrome (serum albumin <2.5 g/dl) 11. any reason for ineligibility suggested by the attending doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To investigate whether night/day UNaV ratio reduce to <1.0 before the night/day BP ratio reduce to <0.9

Secondary Outcome Measures

Name	Time	Method
GFR, Urinary excretion of albumin, potassium, chrolide, angiotensinogen and 8-OHdG, HF and LF/HF obtained by Holter ECG,safety Circadian BP rhythm 1 year after treatment was also studied.